Orexo AB today announced that the European Medicines Agency (EMA) has granted a Marketing Authorization (MA) for Zubsolv (buprenorphine and naloxone), a novel rapidly-disintegrating treatment option for opioid dependence. Zubsolv is a sublingual tablet licensed for people with opioid dependence within a framework of medical, social and psychological treatment. It is the first such therapy to be…